TriSalus director granted RSUs and stock options

TriSalus Life Sciences director William Valle reported equity compensation grants.

(Neutral)

Form Type

Rhea-AI Filing Summary

TriSalus Life Sciences director William Valle reported equity compensation grants. He received 24,553 restricted stock units and 28,201 additional restricted stock units, both payable in common stock. One award is in lieu of 2026 board retainer cash fees and vests in quarterly one-third installments through 2026.

Valle was also granted a director stock option for 56,403 shares of common stock at an exercise price of $2.52 per share, expiring on May 13, 2036. The RSU awards and option generally vest on the one-year anniversary of the May 14, 2026 grant date, subject to his continued service with the company.

Insider Trade Summary

Grant/Award: 109,157 shares

Grant/Award 3 txns

Insider Valle William

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	56,403	$0.00	$0.00
Grant/Award	Common Stock	28,201	$0.00	$0.00
Grant/Award	Common Stock	24,553	$0.00	$0.00

Holdings After Transaction: Director Stock Option (right to buy) — 112,653 contracts (Direct); Common Stock — 83,241 shares (Direct)

Footnotes (3)

F1. Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer.
F2. Represents grant of restricted stock units (the "Retainer RSU Award") payable solely in common stock of the Issuer. The Reporting Person elected to receive the Retainer RSU Award in lieu of 2026 board service retainer cash fees provided for under the Issuer's Non-Employee Director Compensation Policy. The shares subject to the Retainer RSU Award shall vest quarterly in equal one-third installments through the remainder of 2026, subject to the Reporting Person's continued service with the Issuer.
F3. The shares subject to the option shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer.

Key Figures

RSU Award: 24,553 shares Retainer RSU Award: 28,201 shares Director stock option size: 56,403 shares +4 more

7 metrics

RSU Award 24,553 shares Restricted stock units payable in common stock, granted May 14, 2026 vesting after one year

Retainer RSU Award 28,201 shares RSUs in lieu of 2026 board retainer cash fees, vesting quarterly in 2026

Director stock option size 56,403 shares Option covering common stock granted May 14, 2026

Option exercise price $2.52 per share Exercise price for director stock option expiring May 13, 2036

Common shares after first RSU grant 83,241 shares Total common stock holdings following 24,553-share RSU grant

Common shares after second RSU grant 58,688 shares Total common stock holdings following 28,201-share RSU grant entry

Options after grant 112,653 options Total director stock options following 56,403-share option grant

Key Terms

restricted stock units, Retainer RSU Award, Non-Employee Director Compensation Policy, Director Stock Option (right to buy), +1 more

5 terms

restricted stock units financial

"Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Retainer RSU Award financial

"Represents grant of restricted stock units (the "Retainer RSU Award") payable solely in common stock of the Issuer."

Non-Employee Director Compensation Policy financial

"Retainer RSU Award in lieu of 2026 board service retainer cash fees provided for under the Issuer's Non-Employee Director Compensation Policy."

Director Stock Option (right to buy) financial

"Director Stock Option (right to buy) with an exercise price of $2.5200 per share."

board service retainer cash fees financial

"Retainer RSU Award in lieu of 2026 board service retainer cash fees provided for under the Issuer's Non-Employee Director Compensation Policy."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did TriSalus (TLSI) director William Valle report on this Form 4?

Director William Valle reported receiving equity compensation, including restricted stock units and a stock option. These awards increase his potential ownership in TriSalus Life Sciences and are tied to his continued board service and compensation structure during 2026.

How many TriSalus (TLSI) restricted stock units did William Valle receive?

William Valle received 24,553 restricted stock units and a separate grant of 28,201 restricted stock units, both payable solely in TriSalus common stock. These awards vest over time in 2026, conditioned on his continued service with the company as a non-employee director.

What are the terms of William Valle’s TriSalus (TLSI) director stock option?

Valle was granted a director stock option covering 56,403 shares of TriSalus common stock at a $2.52 exercise price. The option fully vests one year after the May 14, 2026 grant date and expires on May 13, 2036, subject to his continued service.

How is the TriSalus (TLSI) Retainer RSU Award structured for William Valle?

The Retainer RSU Award is a restricted stock unit grant Valle elected instead of 2026 board retainer cash fees. The shares underlying this award vest in equal one-third installments quarterly through the remainder of 2026, as long as he continues serving on the board.

Do William Valle’s TriSalus (TLSI) equity awards depend on continued service?

Yes. Both the main RSU award and the director stock option vest fully on the one-year anniversary of the May 14, 2026 grant date, subject to Valle’s continued service. The Retainer RSU Award also vests quarterly through 2026, contingent on ongoing board service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/15/2026 - 04:39 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Valle William

(Last)

(First)

(Middle)

6272 W. 91ST AVENUE

(Street)

WESTMINSTER

COLORADO

80031

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/14/2026		A		28,201⁽¹⁾	A	$0	58,688	D
Common Stock	05/14/2026		A		24,553⁽²⁾	A	$0	83,241	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Director Stock Option (right to buy)	$2.52	05/14/2026		A		56,403		⁽³⁾	05/13/2036	Common Stock	56,403	$0	112,653	D

Explanation of Responses:

1. Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer.

2. Represents grant of restricted stock units (the "Retainer RSU Award") payable solely in common stock of the Issuer. The Reporting Person elected to receive the Retainer RSU Award in lieu of 2026 board service retainer cash fees provided for under the Issuer's Non-Employee Director Compensation Policy. The shares subject to the Retainer RSU Award shall vest quarterly in equal one-third installments through the remainder of 2026, subject to the Reporting Person's continued service with the Issuer.

3. The shares subject to the option shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer.

Remarks:

	/s/ Mary Szela, Attorney-in-Fact	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

TriSalus director granted RSUs and stock options

Rhea-AI Filing Summary

Positive

Negative